NNC0114-0006 clinical trials
Also written NNC0114-0006.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses NNC0114-0006 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NNC0114-0006
- 5
Studies by the year they started
5 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2012 | 3 |
| 2013 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses NNC0114-0006 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell FunctionCompletedPhase 2Novo Nordisk A/SNCT02443155Written as NNC0114-0006
- A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's DiseaseCompletedPhase 2Novo Nordisk A/SNCT01751152Written as NNC0114-0006
- Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid ArthritisCompletedPhase 1Novo Nordisk A/SNCT01565408Written as NNC0114-0006
- A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid ArthritisCompletedPhase 2Novo Nordisk A/SNCT01647451Written as NNC0114-0006
- An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)TerminatedPhase 1Novo Nordisk A/SNCT01689025Written as NNC0114-0006